Mumbai: Pharmaceutical firm Aurobindo Pharma today said it has received approval from the Medicines Control Council (MCC) to manufacture and market nine products in South Africa.

These products are estimated to have a generic market size of ZAR 165 million in the local market, the company said in a filing to the Bombay Stock Exchange.

Aurobindo now has a total of 31 marketing authorisations approved by the MCC, the company added.

Out of the nine products -- Zinoxime and Yomax -- are anti-infective while Auro-Lisinopril Co, Auro-Amlodipine and Lisinozide are cardio-vascular system drug.

The other products that received the approval include -- Auro-Finasteride, Zolid, Lazivir and Profina.

Shares of the company were trading at Rs 330, down 2.21 per cent on the BSE in afternoon trade.
Source : PTI